Literature DB >> 19443321

Expanding access to sterile syringes through pharmacies: assessment of New York's Expanded Syringe Access Program.

James M Tesoriero1, Haven B Battles, Susan J Klein, Erin Kaufman, Guthrie S Birkhead.   

Abstract

OBJECTIVES: To investigate the evolution of pharmacist practices, attitudes, and experiences with the Expanded Syringe Access Program (ESAP), which permits over-the-counter sale of syringes by registered pharmacies in New York State.
DESIGN: Longitudinal study.
SETTING: New York State in 2002 and 2006. PARTICIPANTS: 506 (2002) and 682 (2006) managing pharmacists (response rates approximately 70%) at ESAP-registered pharmacies (n = 346 in both years). INTERVENTION: Mailed surveys (2002 and 2006). MAIN OUTCOME MEASURES: Pharmacist practices, attitudes, and experiences with ESAP over time.
RESULTS: Approximately 75% of pharmacists reported that ESAP had facilitated timely/emergency access to syringes, and more than 90% in each year reported no problems or very few problems administering ESAP. The practice of placing additional requirements on the sale of syringes decreased from 2002 (51.4%) to 2006 (45.1%), while a 55% increase in syringe sales was reported between 2002 (43.3/month) and 2006 (67.1/month). The sale of sharps containers also increased between 2002 (85.2%) and 2006 (92.8%). Community independent pharmacies and those located outside New York City generally expressed more favorable attitudes and experiences with ESAP, although these differences decreased over time.
CONCLUSION: Pharmacy-based syringe access is a viable harm-reduction alternative in the fight against blood-borne diseases, with ESAP now equaling the number of syringes being distributed by syringe exchange programs in New York State. Continued education/training is necessary to increase participation in ESAP and to further reduce barriers to ESAP use.

Entities:  

Mesh:

Year:  2009        PMID: 19443321     DOI: 10.1331/JAPhA.2009.07127

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  8 in total

1.  Pharmacists and harm reduction: A review of current practices and attitudes.

Authors:  Tyler Watson; Christine Hughes
Journal:  Can Pharm J (Ott)       Date:  2012-05

2.  Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013.

Authors:  Ashly E Jordan; Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Denis Nash; David C Perlman
Journal:  Drug Alcohol Depend       Date:  2015-04-13       Impact factor: 4.492

3.  Adverse event associated with a change in nonprescription syringe sale policy.

Authors:  Nickolas D Zaller; Michael A Yokell; Alexandra Jeronimo; Jeffrey P Bratberg; Patricia Case; Josiah D Rich
Journal:  J Am Pharm Assoc (2003)       Date:  2010 Sep-Oct

4.  Using molecular epidemiology to trace the history of the injection-related HIV epidemic in New York City, 1985-2019.

Authors:  Lucia V Torian; Lisa Forgione; Joel O Wertheim
Journal:  AIDS       Date:  2022-02-24       Impact factor: 4.632

5.  Effect of legal status of pharmacy syringe sales on syringe purchases by persons who inject drugs in San Francisco and San Diego, CA.

Authors:  Saira S Siddiqui; Richard F Armenta; Jennifer L Evans; Michelle Yu; Jazmine Cuevas-Mota; Kimberly Page; Peter Davidson; Richard S Garfein
Journal:  Int J Drug Policy       Date:  2015-06-24

6.  Attitudes toward Web application supporting pharmacist-clinician comanagement of postexposure prophylaxis patients.

Authors:  Crystal M Fuller; Alezandria K Turner; Diana Hernández; Alexis V Rivera; Silvia Amesty; Michael D Lewis; Stuart Feldman
Journal:  J Am Pharm Assoc (2003)       Date:  2013 Nov-Dec

Review 7.  Public health in community pharmacy: a systematic review of pharmacist and consumer views.

Authors:  Claire E Eades; Jill S Ferguson; Ronan E O'Carroll
Journal:  BMC Public Health       Date:  2011-07-21       Impact factor: 3.295

8.  Acceptability and feasibility of a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program in the Midwestern United States.

Authors:  Joshua P Havens; Kimberly K Scarsi; Harlan Sayles; Donald G Klepser; Susan Swindells; Sara H Bares
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.